Federal Register / Vol. 89, No. 194 / Monday, October 7, 2024 / Notices 81089 

DATES: Comments regarding this 

information collection are best assured 

of having their full effect if received 

within 60 days of the date of this 

publication. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments, submit 

comments in writing, or request more 

information on the proposed project, 

contact Candace Maynard, Branch 

Chief, Cancer Information Service 

Branch, CISB/OCPL, 9609 Medical 

Center Drive, Rockville, MD 20850, or 

call non-toll-free number 240–276–6657 

or email your request, including your 

address to: deatonc@mail.nih.gov. 

Formal requests for additional plans and 

instruments must be requested in 

writing. 

SUPPLEMENTARY INFORMATION: Section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 requires written 

comments and/or suggestions from the 

public, and affected agencies are invited 

to address one or more of the following 

points: (1) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

function of the agency, including 

whether the information will have 

practical utility; (2) The accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; (3) 

Ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Ways to minimize the 

burden of the collection of information 

on those who are to respond, including 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology. 

Proposed Collection Title: Collection 

of Customer Service, Demographic, and 

Smoking/Tobacco use Information from 

the National Cancer Institute’s (NCI) 

Cancer Information Service (CIS), 0925– 

0208, Expiration Date 03/31/2025, 

REVISION, National Cancer Institute 

(NCI), National Institutes of Health 

(NIH). 

Need and Use of Information 

Collection: The National Cancer 

Institute (NCI) currently collects (1) 

customer service and demographic 

information from clients of the Cancer 

Information Service (CIS) to properly 

plan, implement, and evaluate cancer 

education efforts, including assessing 

the extent by which the CIS reaches and 

impacts underserved populations; (2) 

smoking/tobacco use behavior of 

individuals seeking NCI’s smoking 

cessation assistance through the CIS to 

provide smoking cessation services 

tailored to the individual client’s needs 

and track their smoking behavior at 

follow up. This is a request for OMB to 

approve a revised submission for an 

additional three years to provide 

ongoing customer service collection of 

demographic information and collection 

of brief customer satisfaction questions 

from NCI Cancer Information Service 

Clients for the purpose of program 

planning and evaluation. 

OMB approval is requested for 3 

years. Respondents’ only cost is their 

time. The total estimated annualized 

burden hours are 6,343. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Category of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average time 

per response 

(in hours) 

Total annual 

burden hours 

Demographic & Customer Satisfaction Questions 

(Appendix 1A or 1AB).

Individuals ..................... 15,754 1 3/60 788 

Demographic & Customer Satisfaction Questions 

(Appendix 1B).

Individuals ..................... 17,589 1 2/60 586 

Smoking Cessation ‘‘Intake’’ Questions (Appendix 1C).Individuals ..................... 8,839 1 6/60 884 

Smoking Call Backs (Appendix 1D) ..................... Individuals ..................... 8,840 1 4/60 589 

VA Call Backs (Appendix 1E) ............................... Individuals ..................... 26,055 1 4/60 1,737 

Cancer Info Call Backs (Appendix 1F) ................. Individuals ..................... 1,841 1 4/60 123 

Email Intake Form (Appendix 2) ........................... Individuals ..................... 9,740 1 10/60 1,623 

Demographic & Customer Satisfaction Questions 

(Appendix 9).

Individuals ..................... 400 1 2/60 13 

Totals ............................................................. ....................................... ........................ 113,191 ........................ 6,343 

Dated: October 2, 2024. 

Diane Kreinbrink, 

Project Clearance Liaison, National Cancer 

Institute, National Institutes of Health. 

[FR Doc. 2024–23127 Filed 10–4–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Anti-KK–LC–1 T Cell 

Receptors 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this notice to T-Cure 

Biosciences, Inc. (‘‘T-Cure’’) located in 

Calabasas, California. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before October 22, 2024 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Suna Gulay French, Ph.D., 

Technology Transfer Manager, NCI 


lotter on DSK11XQN23PROD with NOTICES1
81090 Federal Register / Vol. 89, No. 194 / Monday, October 7, 2024 / Notices 

Technology Transfer Center, 9609 

Medical Center Drive, RM 3W–204, 

MSC 9702, Bethesda, MD 20892–9702 

(for business mail), Rockville, MD 

20850–9702; Telephone: (240)–276– 

5530; Email: suna.gulay@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

1. United States Provisional Patent 

Application No. 62/327,529, filed April 

26, 2016 and entitled ‘‘Anti-KK–LC–1 T 

Cell Receptors’’ [HHS Reference No. E– 

153–2016–0–US–01]; 

2. PCT Patent Application No. PCT/ 

US2017/027865, filed April 17, 2017 

and entitled ‘‘Anti-KK–LC–1 T Cell 

Receptors’’ [HHS Reference No. E–153– 

2016–0–PCT–02]; 

3. Australian Patent No. 2017258745, 

issued July 14, 2022 and entitled ‘‘AntiKK–LC–1 T Cell Receptors’’ [HHS 

Reference No. E–153–2016–0–AU–03]; 

4. Canadian Patent Application No. 

3021898, filed April 17, 2017 and 

entitled ‘‘Anti-KK–LC–1 T Cell 

Receptors’’ [HHS Reference No. E–153– 

2016–0–CA–04]; 

5. European Patent No. 3448882, 

issued November 24, 2021 and entitled 

‘‘Anti-KK–LC–1 T Cell Receptors’’ [HHS 

Reference No. E–153–2016–0–EP–05]; 

a. Validated in the following 

jurisdictions: CH, DE, BE, DK, ES, FI, 

FR, GB, IE, IT, NL, NO and SE. 

6. U.S. Patent No. 11,352,410, issued 

June 7, 2022 and entitled ‘‘Anti-KK–LC– 

1 T Cell Receptors’’ [HHS Reference No. 

E–153–2016–0–US–06]. 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide and the 

field of use may be limited to the 

following: 

‘‘1. Development, manufacture, and 

commercialization of autologous T cell 

therapy products, including T cells with 

stem-like properties, engineered via 

retrovirus-mediated gene transfer to 

express T cell receptors reactive to KitaKyushu Lung Cancer Antigen 1 (KK– 

LC–1), as claimed in the Licensed Patent 

Rights; such products to be developed 

for treatment of patients carrying HLA– 

A*01:01 histocompatibility haplotype, 

and diagnosed with a cancer expressing 

KK–LC–1 protein (‘‘KK–LC–1 Targeting 

TCR–T Products’’). 

2. Development, manufacture, and 

commercialization of a combination 

therapy for the treatment of KK–LC–1 

expressing human cancers, independent 

of their HLA phenotype, wherein the 

treatment comprises: 

a. Modification of the patient’s tumor 

using Licensee’s proprietary technology 

to express the HLA–A*01:01 restriction 

element, and 

b. Treatment with the KK–LC–1 

Targeting TCR–T Products. 

For the avoidance of doubt, 

specifically excluded from these Fields 

of Use are Natural Killer cell therapy 

products engineered via viral vectors 

(including lentivirus or retrovirus) to 

express the TCR(s) claimed in the 

Licensed Patent Rights.’’ 

This technology discloses isolated T 

cell receptors (TCR) reactive to the KitaKyushu lung cancer antigen 1 (KK–LC– 

1) within the context of human 

leukocyte antigen (HLA) A*01:01. KK– 

LC–1 is expressed by various epithelial 

cancers including carcinomas of the 

bladder, cervix, stomach, breast, lung, 

and pancreas. Due to its minimal 

expression in normal tissues, this 

antigen may be targeted on KK–LC–1- 

expressing tumors with minimal normal 

tissue toxicity. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: October 1, 2024. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2024–23029 Filed 10–4–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Biological Chemistry 

and Macromolecular Biophysics Integrated 

Review Group; Drug Discovery and 

Molecular Pharmacology B Study Section. 

Date: October 31-November 1, 2024. 

Time: 8:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Razvan Cornea, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 904L, 

Bethesda, MD 20892, (301) 480–1955, 

cornearl@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Imaging and 

Bioengineering Technology for Visual 

Systems (IBV). 

Date: November 4–5, 2024. 

Time: 8:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Watergate, 2650 Virginia 

Avenue NW, Washington, DC 20037. 

Contact Person: Susan Gillmor, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (240) 762–3076, susan.gillmor@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Learning, Memory, Language, 

Communication and Related Neuroscience. 

Date: November 4–5, 2024. 

Time: 8:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Canopy by Hilton, 940 Rose Avenue, 

North Bethesda, MD 20852. 

Contact Person: Alexei Kondratyev, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5200, 

MSC 7846, Bethesda, MD 20892, 301–435– 

1785 kondratyevad@csr.nih.gov. 


lotter on DSK11XQN23PROD with NOTICES1